Scenic Biotech and Stanford University have published a study identifying PLA2G15 as a new drug target in neurodegenerative and metabolic diseases, potentially enabling future treatments for ...

Scientists have developed a new drug, SHP1705, that targets hijacked circadian clock proteins used by glioblastoma stem cells to grow and resist treatment. Glioblastoma, the most aggressive form of ...

The body undergoes changes with age that can lead to conditions like sarcopenia and osteoarthritis, burdening individuals and healthcare systems. Find out how Rejuvenate Biomed uses AI to decode ...

CatalYm announces new preclinical data showing that its clinical-stage antibody, visugromab, can overcome resistance to antibody-drug conjugates (ADCs), showing potential to restore anti-tumour immune ...

Enedra Therapeutics has secured new funding to advance its AI-driven CASPAROV platform, aimed at developing therapies for difficult-to-treat cancers The London based drug discovery company, Enedra ...

Japanese researchers have developed a new enzyme technology that can precisely alter the levels of mutated mitochondrial DNA in patient-derived stem cells, offering a promising new approach for ...

Cell and gene therapy is rapidly transforming the treatment of complex diseases, yet scaling production efficiently remains a challenge. Dr Tia Harmon from PHC Corporation of North America explores ...

The partnership allows for the further development of AI-designed RNA-targeted therapies for a range of diseases. Creyon Bio, Inc. (Creyon) has announced a landmark global licensing and multi-target ...

Explore the new NaV1.9 screening assay that accelerates drug discovery for pain treatment and targets non-opioid pathways.

Huntington’s disease remains a major challenge, but allele-selective gene editing offers new hope. By targeting only the mutant gene, this approach could provide a one-time, durable treatment. Life ...

A new study reveals how tumours hijack fat metabolism to suppress immune responses – and how a novel antibody, PLT012, may reverse this effect, offering new hope for treating immunotherapy-resistant ...